Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This will be a dose block-randomized, double-blind, active and placebo controlled, single and
multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic /
pharmacodynamic characteristics. Adverse events, physical examinations, vital signs, ECG and
laboratory tests will be conducted for safety/tolerability evaluation and serial blood
samples and urine collections for pharmacokinetic and pharmacodynamic evaluations will be
conducted at specified time points.